Literature DB >> 32291456

Entecavir prophylaxis for hepatitis B virus reactivation in patients with CAR T-cell therapy.

Wenyue Cao1,2, Jia Wei1,2, Na Wang1,2, Hao Xu1,2, Min Xiao1,2, Lifang Huang1,2, Yang Cao1,2, Chunrui Li1,2, Yi Xiao1,2, Chaojiang Gu3,4, Shangkun Zhang4, Dengju Li1,2, Yichen Zhang1,2, Tongcun Zhang3,4, Jianfeng Zhou1,2, Liang Huang1,2.   

Abstract

Entities:  

Year:  2020        PMID： 32291456     DOI： 10.1182/blood.2020004907

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  10 in total

Review 1.  Infectious complications, immune reconstitution, and infection prophylaxis after CD19 chimeric antigen receptor T-cell therapy.

Authors:  Kitsada Wudhikarn; Miguel-Angel Perales
Journal:  Bone Marrow Transplant       Date:  2022-07-15       Impact factor: 5.174

2.  Acute liver failure due to hepatitis B virus reactivation induced by doxorubicin and cyclophosphamide chemotherapy for adjuvant treatment of breast cancer: A case report.

Authors:  Tahir Hakami
Journal:  Clin Case Rep       Date:  2022-05-23

3.  T Cell Defects: New Insights Into the Primary Resistance Factor to CD19/CD22 Cocktail CAR T-Cell Immunotherapy in Diffuse Large B-Cell Lymphoma.

Authors:  Jiachen Wang; Kefeng Shen; Wei Mu; Weigang Li; Meilan Zhang; Wei Zhang; Zhe Li; Tong Ge; Zhoujie Zhu; Shangkun Zhang; Caixia Chen; Shugang Xing; Li Zhu; Liting Chen; Na Wang; Liang Huang; Dengju Li; Min Xiao; Jianfeng Zhou
Journal:  Front Immunol       Date:  2022-04-27       Impact factor: 8.786

4.  [The Chinese consensus for the CAR-T cell therapy in multiple myeloma (2022 version)].

Authors: 
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2022-04-14

5.  [The consensus on the prophylaxis and treatment of HBV reactivation in B or plasma cell-directed CAR-T cell therapy(2021)].

Authors: 
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2021-06-14

6.  Viral infection/reactivation during long-term follow-up in multiple myeloma patients with anti-BCMA CAR therapy.

Authors:  Di Wang; Xia Mao; Yimei Que; Menglei Xu; Yuhang Cheng; Liang Huang; Jue Wang; Yi Xiao; Wen Wang; Guang Hu; Shangkun Zhang; Tongcun Zhang; Chunrui Li; Jianfeng Zhou
Journal:  Blood Cancer J       Date:  2021-10-18       Impact factor: 11.037

7.  Donor-Derived CD7 CAR-T Therapy Followed by Allogeneic Hematopoietic Stem Cell Transplantation for Acute T-Lymphocytic Leukemia Associated With Hepatitis B: A Case Report.

Authors:  Zhihui Li; Fanqiao Meng; Jing Li; Tong Wu
Journal:  Front Immunol       Date:  2022-07-12       Impact factor: 8.786

8.  Risk of HBV reactivation in relapsed or refractory diffuse large B-cell lymphoma patients receiving Bruton tyrosine kinase inhibitors therapy.

Authors:  Ying Ni; Lixia Gao; Yan Lu; Shiguang Ye; Lili Zhou; Wenbin Qian; Aibin Liang; Ping Li
Journal:  Front Immunol       Date:  2022-08-31       Impact factor: 8.786

9.  MYC/BCL2/BCL6 triple hit and TP53 deletion in a case of high-grade B cell lymphoma receiving CAR T cell immunotherapy.

Authors:  Jiachen Wang; Zhen Shang; Jue Wang; Jinhuan Xu; Weigang Li; Yuqi Guan; Li Yang; Wei Zhang; Kefeng Shen; Meilan Zhang; Jin Wang; Liting Chen; Qinlu Li; Cheng He; Na Wang; Liang Huang; Yi Xiao; Min Xiao; Jianfeng Zhou
Journal:  J Immunother Cancer       Date:  2021-06       Impact factor: 13.751

10.  Case Report: Post-CAR-T Infusion HBV Reactivation in Two Lymphoma Patients Despite Entecavir Preventive Therapy.

Authors:  Yaxian Ma; Li Yang; Yuhan Bao; Yang Yang; Liting Chen; Miao Zheng
Journal:  Front Immunol       Date:  2021-10-08       Impact factor: 7.561
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.